GlassScriptPhysician profile
Keith O Jones
NPI 1316131568
$544.21
in general payments reported to CMS, 2019-2025
13 companies · $128 in 2025
The $128 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $128 · 2020: $98.89 · 2021: $66.19 · 2022: $67.31 · 2023: $39.99 · 2024: $16.68 · 2025: $128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $184.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $89.90 | 2025 | Linq II |
| Allergan, INC. | $84.39 | 2020 | |
| Ucb, INC. | $60.83 | 2019-2023 | Briviact |
| Abbvie INC. | $58.16 | 2021-2024 | |
| Chiesi USA, INC. | $46.42 | 2022 | |
| Blue Earth Diagnostics | $37.68 | 2023-2025 | Posluma |
| Supernus Pharmaceuticals, INC. | $37.20 | 2019 | |
| Sunovion Pharmaceuticals INC. | $36.73 | 2019 | |
| Viz.Ai, INC. | $31.36 | 2021 | |
| Genentech USA, INC. | $18.32 | 2025 | |
| Misonix INC | $14.50 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $14.48 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.